Deutsche Bank has a research note on Bristol-Myers Squibb BMY, as it discusses Apixaban. It has a Buy rating and a $31.50 price target on shares.
In a note to clients, Deutsche Bank writes, "Xarelto...BI's Pradaxa has superior efficacy to warfarin, but was equivalent on bleeds, while Xarelto was non-inferior on efficacy and bleeds (though better on fatal and intracranial bleeds). The top line results for apixaban reported this evening should support a strong commercial opportunity for apixaban in this large market versus the competition. We reiterate our BUY ratings on BMY and PFE (CP $20.26), and our $1.5 billion estimate for apixaban in 2015."
Shares of BMY are up $2.01 in pre-market trading to $29.75, a gain of 7.25%.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in